RVTY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Revvity is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some constructive technical momentum and positive congressional buying, but the fundamental picture is mixed: growth has been slow, margins have compressed, EPS has declined over time, and analysts still see valuation as stretched. Since the user is impatient and does not want to wait for an ideal entry, my direct opinion is to hold off on buying today rather than chase it at this level.
RVTY is in a short-term uptrend: SMA_5 is above SMA_20 and SMA_200, and MACD remains positive, though the histogram is contracting, which suggests momentum is still positive but losing strength. RSI_6 at 76.5 is elevated, indicating the stock is extended rather than attractive for a fresh long entry. Price at 113.76 is just below R1 resistance at 114.36 and above the pivot of 107.19, so the stock is near resistance rather than at a clear discount. The technical setup is bullish but not ideal for a beginner entering now.
["Bernstein resumed coverage with Market Perform and noted sector conditions are improving.", "TD Cowen remains Buy-rated and cited improving Pharma/A&G demand, solid software strength, and management confidence in margin ramp.", "China ImmunoDx divestiture removed a key risk, according to TD Cowen.", "Congressional trading data shows 2 purchase transactions and no sales over the last 90 days.", "Price action remains above key moving averages, indicating ongoing technical support."]
["Recent news says organic revenue growth has averaged only 2.9% annually over the past two years.", "Adjusted operating margin has fallen 6 percentage points over five years to 27%.", "EPS has declined 14.7% annually over the last five years.", "Analysts said the stock looks overpriced at a forward P/E of 20.3.", "Barclays, JPMorgan, Stifel, and Wolfe are more cautious or neutral, and some have lowered price targets.", "The stock is near resistance, and RSI is elevated, reducing near-term entry attractiveness."]
Latest quarter financials were not provided due to a financial snapshot error, so I cannot assess the exact quarter season. Based on the supplied fundamentals, the broader financial trend is not strong: organic growth has been modest, margins have compressed, and EPS has declined over the multi-year period. That suggests the latest reported quarter likely needs to show clear acceleration before the stock becomes a compelling long-term buy.
Analyst sentiment is mixed to cautious. Bernstein initiated/resumed with Market Perform and $115 PT, Wolfe came in at Peer Perform, JPMorgan cut its target to $90 with Neutral, Barclays is Equal Weight with a lower target, while TD Cowen and Baird remain constructive with higher targets. The Wall Street pros and cons view is balanced but leans cautious: bulls point to improving demand, software strength, and margin recovery potential, while bears point to valuation, slowing growth, and margin pressure. Overall, analysts are not broadly bullish enough to justify a decisive buy at the current price.
